DBVT

Châtillon, France, September 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in September: 2026 Cantor Global Healthcare Conference – September 9, 2026 Format:         Fireside Chat Time:            1:00pm ETLocation:       New York, NY Citi's 2026 Biopharma Back to School Conference – September 10, 2026 Format:         1 on 1 MeetingsLocation:       New York, NY H.C. Wainwright 28 th Annual Global Investment Conference – September 15, 2026 Format:         Fireside ChatTime:            3:00pm ETLocation:      New York, NY Live webcasts of the fireside chats will be available on the Events section of the Company's website here and will be available for 90 days after the event.

Artisan International Small-Mid Fund portfolio modestly trailed the MSCI ACWI ex USA SMID Index in Q2. On an individual company basis, NICE, Landis+Gyr and DBV Technologies were the largest Q2 detractors. Our top contributors for the quarter were Rohm, LivaNova and Glanbia.

Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, 2026, (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form of American Depositary Shares (“ADSs”), for total gross proceeds to the Company of approximately $50 million, before deducting sales agent commissions and offering expenses payable by the Company, to RA Capital Management, L.P (“RA Capital”) through Citizens JMP Securities, LLC (“Citizens”), acting as sales agent. Each ADS represents the right to receive five Ordinary Shares of the Company.

DBV Technologies is rated a buy, with a 24% upside to a $17 FY 2027 price target as Viaskin nears BLA submission. DBVT's transition from research to commercial readiness is evident, with rising sales/marketing spend and declining research tax credits signaling operational progress. The key catalyst is the planned Q3 2026 BLA submission, expected to trigger a 10-month FDA review and potential commercial launch in 2027.

Châtillon, France, July 17, 2026 DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that it has filed a new automatically effective shelf registration statement on Form S-3ASR (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”), which includes a base prospectus and a sales agreement prospectus supplement refreshing the Company's previously established at-the-market offering program (the “ATM Program”) by filing a prospectus supplement for sales of up to $150 million of American Depositary Shares (“ADS”). The ATM Program was established pursuant to a sales agreement dated September 5, 2025, (the “Sales Agreement”) with Citizens JMP Securities, LLC (“Citizens”), acting as sales agent, under which the Company may offer and sell, from time to time, ADSs, each ADS representing five ordinary shares of the Company, having an aggregate offering price of up to $150 million, subject to French regulatory limits.

DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript

DBV Technologies NASDAQ: DBVT said it is continuing preparations for a planned third-quarter 2026 Biologics License Application submission for its VIASKIN Peanut Patch in children ages 4 through 7, while also building commercial infrastructure ahead of a potential U.S. launch.

Châtillon, France, July 16, 2026 DBV Te c hnologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the semester ended June 30, 2026, of its Half-Year Report with the French market authority, “Autorité des Marchés Financiers” (“AMF”). The 2026 Half-Year Report can be consulted or downloaded from the Company's website (www.dbv-technologies.com) in the section Investors/Financial Information, and on the AMF website (www.amf-france.org), in French only.

Châtillon, France, July 16, 2026 DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026 Reported cash and cash equivalents of $174.9 million as of June 30, 2026, funding into third quarter of 2027 DBV will host a conference call today, July 16, at 5:00pm ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today reported financial results for the Second Quarter and Half-Year of 2026. The quarterly and Half-Year financial statements were approved by the Board of Directors on July 16, 2026.

Châtillon, France, July 14, 2026 DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026 Company to host investor conference call and webcast at 5:00 p.m. ET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, July 16th, at 5:00 p.m.